Zoom will change nothing?

The tech industry always knows how the future will be.

Why, it's creating it, so it's got something of an inside track at the bookies.

Not everyone, however, is convinced about Techworld's slightly smug infallibility.

On Thursday, Delta emailed me to announce it had lost the GDP of a small, robust country. $12.4 billion.

Certainly, the coronavirus has wrecked airlines' ability to do much but get many free billions from the government. Working from home seems to be the new permanent way for many people.

You might think, then, that the analysts' call to herald such an announcement would be grim, brutal, and swift. Instead, Delta's executives looked into the future and insisted the tech industry has got it all wrong.

For many months, wise tech lords like SoftBank's Masayoshi Son and Melinda's Bill Gates have claimed that business travel will never be what it once was. Why, Zooming and Teamsing have made flying unnecessary, haven't they?

Not so long ago, Natarajan Chandrasekaran, chairman of Indian conglomerate Tata Sons, claimed he'd done $2 billion worth of deals in just five or six Zoom calls.

Yet here were Delta's executives insisting this was all hocus diluted with overripe pocus.

As The Points Guy reported, Delta CEO Ed Bastian mused: "I wouldn't draw the conclusion that corporate travel is impaired at all."

At all? In any way? Not even in 12.4 billion ways?

Bastian and the airline's president Glen Hauenstein insist they have corporate travelers just where they want them. They believe vaccines will make an enormous difference.

Hauenstein also said the airline's determined decision to block middle seats -- amid considerable controversy as to whether filling middle seats increases the risk of getting the virus -- enhanced its image with corporate travelers. He said revenue premiums have never been as exalted.

"Customers value the Delta difference (including) the least amount of sellable capacity," he said.

Scarcity sells. Instinctively, every flyer prefers having an empty seat next to them. Unless it was supposed to be occupied by a lover who didn't turn up.

I still wonder whether Delta is entirely correct. Travel executives at tech companies have told me that they -- and, more delightfully, their bosses -- instantly see the savings that better video conferencing has brought.

Why would companies ever, some insist, revert to spending so much money on travel?

The CEOs of American Airlines and United believe nothing -- and certainly not the likes of Zoom -- can replace the face-to-face needs of business. Those needs, however, have surely undergone something of a modification in the last nine months.

I can believe that Delta has done its research. I can believe its corporate customers are telling it nice things. But as Teams and Zoom -- and even Webex -- accelerate the joys of their offerings, I'm not so convinced there'll be a swift -- or complete -- return to corporate flying.

Delta's research is based on its business customers saying what they're going to do in the future. 40% say they'll be back to normal flying by 2022. I don't even know how I'm going to behave next week.

Moreover, the tech industry has a creepily effective way of altering habits we thought would last forever. Remember owning music? It's also very good at creating entirely new cost parameters that CFOs quite adore. Last October, Amazon said it had already saved $1 billion on corporate travel.

Then again, I do believe there'll soon be enormous enthusiasm for getting away from it all to anywhere sunny that'll let us in. Just so we can breathe quietly and forget 2020.

Wouldn't it be a beautiful twist of fortune if, in the near future, companies worked far harder at getting their employees to fly away and relax with their loved ones, rather than to eat steak and drink whiskey with someone they don't even like?

Read more:
Delta just offered a brave lesson in listening to customers, not tech - ZDNet

TipRanks

Risk and reward often travel hand-in-hand, making the stock market both lucrative and dangerous. Among the best exemplars of this axiom are the penny stocks, those equities priced at $5 or less. With that low price comes the potential for extreme gains, as even an incrementally small price increase will translate to a high percentage gain.JPMorgan's Head of Small and Midcap Equity Strategy, Eduardo Lecubarri, sees both the opportunities and dangers in the current market environment and the great potential of small-cap stocks that have room to run.1Q may be rocky following the strong gains since Nov and the fact that valuations are sitting on all-time highs. However, the year long outlook is encouraging due to far more powerful fundamental tailwinds. Such a positive backdrop is likely to keep investors chasing those few stocks that still offer big recovery upside, as they seem to have started to do YTD. It is for this reason that we would encourage investors to build their portfolios now and see things through in the event of any consolidation phase that may come in Q1, Lecubarri wrote.Taking the risk into consideration, we used TipRanks database to find compelling penny stocks with bargain price tags. The platform steered us towards two tickers sporting Strong Buy consensus ratings from the analyst community. Not to mention substantial upside potential is on the table. We are talking returns of at least 300% over the next 12 months, according to the analysts.AcelRx Pharmaceuticals (ACRX)Opioids have made headlines in recent years, and for all the wrong reasons. These potent pain relief drugs are also dangerously addictive a factor that has led to the opioid epidemic in the US. AcelRx is a pharmaceutical company dedicated to the creation of safer treatments for acute pain, developing synthetic opioid drugs for sublingual (under the tongue) dosing.The companys main product, Sufentanil, was approved by the FDA under the name Dsuvia in 2018, and by the EU as Dzuveo that same year. A second sublingual Sufentanil system, under the name Zalviso, has also been approved for use by the EU, and is in Phase 3 trial in the US.In its most recent earning report, the company showed $1.4 million at the top line, driven by $1.3 million in product sales. The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year.Against this backdrop, several members of the Street believe ACRXs $1.40 share price looks like a steal.Cantor analyst Brandon Folkes is upbeat on Dsuvias prospects as an alternative to current opioid treatments, and he believes that potential will boost the companys stock.With the launch of Dsuvia, we believe investor focus can now shift to launch metrics and peak sales potential for the product. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. We believe that Dsuvia offers an advancement in delivery of adequate pain treatment by eliminating the need for an invasive and time-consuming IV set-up in the emergency room, as well as an outpatient, or post-surgery, setting. Despite hospital launches taking time, we expect the uptake of Dsuvia to drive revenue upside beyond the Street's current estimates, which, in turn, could drive the stock higher from current levels, Follked opined.In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months. (To watch Folkes track record, click here)Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, ACRX has a Strong Buy consensus rating. Based on the $7 average price target, shares could soar 407% in the next year. (See ACRX stock analysis on TipRanks)NuCana (NCNA)NuCana is a biopharma company focused on new cancer treatments. The companys goal is to provide effective treatments for biliary, breast, colorectal, ovarian, and pancreatic cancers while avoiding the complications and side effects of current chemotherapy treatments. NuCana uses a phosphoramidate chemistry technology called ProTide to create a class of drugs that will surmount the limitations of the existing nucleotide analogs behind many chemotherapy drugs. NuCanas ProTides have already been used in Gileads antiviral drug Sovaldi.In May of last year, NuCana announced the restart of its Phase III trial on Acelarin, the drug candidate furthest along the companys pipeline, as a treatment for biliary tract cancers. The study encompasses over 800 patients in 6 countries and is currently ongoing. In November, the company published data described as encouraging from the Phase Ib study of the same drug.While Acelarin is the flagship drug in the pipeline, NuCana has two other prospects under development. NUC-3373 is in Phase I trial as a treatment for solid tumors and colorectal cancers, and NUC-7738 is a second pathway under investigation for applications to advanced solid tumors. Of these three, the colorectal study is the farthest advanced.Writing from Truist, 5-star analyst Robyn Karnauskas sees the pipeline as key to NuCanas investor potential.We believe investors have overlooked the fact that NCNA is a platform Company that we believe is validated, as defined by the production of clinical products. We like that it has brought 3 products to the clinic, including one novel drug and two improved cornerstone chemos. The data suggest to us that the platform works and can produce better chemos [] While investors are mostly focused on Acelarin, we believe investors should also focus on NUC-3373, another core to our platform-based thesis that has data expected in 1H2021, Karnauskas noted.To this end, Karnauskas puts a $22 price target on NCNA, suggesting the stock has room for 384% growth ahead of it, along with a Buy rating. (To watch Karnauskas track record, click here)Overall, NCNA's Strong Buy consensus rating is unanimous, and based on 4 recent reviews. Shares have an average price target of $17.33, suggesting a 270% one-year upside from the current trading price of $4.69. (See NCNA stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more here:
Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative...

Puppies have the potential to bring enormous benefits to their owners lives and can be an asset during uncertain times, including lockdown. That said, caring for a young animal is not without its challenges. With more than one in four puppy buyers during the pandemic admitting it was an impulse decision, there are genuine concerns for the future of the animals taken on during this time.

The success of a long-term dog-owner relationship depends on building a good foundation. Here are six things every owner needs to know about looking after a puppy and developing a long-lasting relationship with their new best friend.

While many new owners romanticise the idea of taking long walks with a frolicking puppy, the reality is young dogs, especially larger breeds, should not be allowed too much exercise. Puppies have a lot of energy, but their bones, joints and growth plates are soft and can be easily damaged.

Too much exercise is almost as harmful as not enough. Over-activity at the wrong age leads to health problems including hip dysplasia, growth deformation and movement disorders.

There is no exact science on the optimum amount of time puppies should be walked for. However, a general rule of thumb is five minutes per month of age, twice a day. By this logic, a 16-week-old puppy would need a daily total of only 40 minutes exercise.

Vaccinating your puppy is one of the most important things to be done in the first few weeks as a new owner. Vaccinations can protect dogs from a wide variety of potentially dangerous pathogens including parvovirus, kennel cough, hepatitis and leptospirosis.

Puppies typically receive their first set of vaccinations around eight to 10 weeks of age, with another set two to three weeks later, although protocols vary. Puppies are not advised to come into contact with un-vaccinated dogs until they are fully protected, so walks in the park are off limits. However, pups can still be carried around the neighbourhood to facilitate socialisation.

Dogs have a number of important stages of development, one being the socialisation period, thought to lie between three and 16 weeks of age. Within this relatively short window of opportunity, puppies need to be exposed to as many different people, animals and situations as possible.

Failure to socialise your puppy can result in a strong fear of these stimuli later in life and, in some cases, the development of resistant behaviour problems. Dogs that are denied contact with children may become overly reactive in their presence, lunging towards them and even attempting to bite.

The importance of putting effort into exposing puppies to the sights, sounds and smells of as many different stimuli and situations as possible cannot be overemphasized. Doing so will allow your dog to navigate life more easily.

Read more: Young dogs might be more similar to human teenagers than we think: new research

Lockdown has resulted in a dramatic increase in the amount of time owners spend with their pets, which could lead to an increase in canine separation anxiety when owners return to work. This problem is believed to stem from an over-attachment between the animal and its caregiver, and one that frequently results in animals being rehomed.

Typical symptoms of this anxiety disorder include urinating or defecating indoors, barking and whining, destruction of the home, escape attempts or self-mutilation whenever the pet is left alone. Separation anxiety is difficult to treat successfully.

It is important to put effort into preventing over-attachment from an early stage, by gradually increasing the length of time the animal spends alone. Various enrichment tools can help the puppy feel relaxed during these periods of separation. Things like pheromone diffusers, classical music or odourants are renowned for their relaxing properties.

While it can be tempting to give your puppy leftovers from the table, there is a long list of foods that can be toxic to dogs. For example, chocolate, especially the dark variety, contains the stimulant theobromine. If ingested, this can damage dogs guts, heart, central nervous system or kidneys, leading to vomiting, diarrhoea, hyperactivity, seizures, and even death.

Onions, garlic and chives, in all forms, can cause damage to dogs red blood cells, eventually leading to anaemia. Xylitol, an artificial sweetener found in foods like sugar free chewing gum, some peanut butters and some sweets, can cause dramatic drops in blood sugar, and, in some cases, liver failure.

The list of other foods that are dangerous to dogs is quite extensive, including, among others, caffeine, alcohol, grapes and raisins. Owners should familiarise themselves with the list of foods that are harmful to dogs and seek immediate veterinary advice in the event of ingestion.

Puppies are notorious for eating anything and everything. Many seem to regard the garden as their own personal larder. Unfortunately, there are numerous botanical hazards that owners need to be aware of.

Certain bulbs, like daffodils, and house plants like poinsettias should be avoided. Seeds and foliage like acorns, ivy and mistletoe can all have a life-threatening impact on dogs. Early signs of toxicosis can include vomiting, diarrhoea and salivation, with more serious effects, such as liver and kidney damage, taking up to two days to manifest themselves. Again, veterinary care must be sought immediately if an owner suspects their puppy has eaten any potentially poisonous plant material.

Being aware of these important tips will help keep your puppy healthy and happy, bringing you a lifetime of joy. Getting a puppy is extremely exciting, but just a little bit of thought and planning will make sure you and your pup get off to the best start possible.

See the original post here:
Six tips for looking after your new puppy, according to science - The Conversation UK

Canine Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.The global Canine Stem Cell Therapy Market size is expected to Expand at Significant CAGR of +4% during forecast period (2020-2026).The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level.

Get Sample Copy of this Report @:

https://www.a2zmarketresearch.com/sample?reportId=21262

Top Companies of this Market includes:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos.

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global Canine Stem Cell Therapy market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Canine Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Canine Stem Cell Therapy market.

Get up to 25% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=21262

The cost analysis of the Global Canine Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Global Canine Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

Allogeneic Stem CellsAutologous Stem cells

Market Segmentation by Application:

Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

Reasons for buying this report:

Table of Contents

Global Canine Stem Cell Therapy Market Research Report 2021

Chapter 1 Canine Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Canine Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=21262

If you have any special requirements, please let us know and we will offer you the report as you want.

https://factorygate.co.uk/

More here:
Impact of COVID-19 on Canine Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | VETSTEM BIOPHARMA, Cell...

Global Canine Stem Cell Therapy Market Report available at AllTheResearch provides a roadmap of the Canine Stem Cell Therapy industry which makes up for the scope of product, market revenue cycle, new opportunities, CAGR, sales volumes, and figures. The demand for Canine Stem Cell Therapy is expected to grow significantly as the industry becomes increasingly popular. The two major factors examined in this report include market revenue and market size.

The Canine Stem Cell Therapy market study is an in-depth analysis of this industry that effectively covers all the aspects related to this industry over the projected period and the primary development trends of the market, over the forecast period. This report on the global Canine Stem Cell Therapy market is designed to serve as a ready-to-use guide for developing accurate pandemic management programs allowing market players to successfully emerge from the crisis and retract numerous gains and profits.

TheCanine Stem Cell TherapyMarket size was valued at US$118.5 Mn in 2018and is expected to grow at a compound annual growth rate (CAGR) of 9.3% for the forecast period ending2026reaching a Market value of US$ 240.7 Mn.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of Canine Stem Cell Therapy market report at:https://www.alltheresearch.com/sample-request/206

Competitive Landscape:

A lot of companies are trying to make the market for the global Canine Stem Cell Therapy prosper with high growth opportunities. These segments are known for extensive participation in taking the market ahead. AllTheResearch recorded their recent steps to gauge in which direction the market is moving and find better growth possibilities there.

The Canine Stem Cell Therapy Market Report Covers Major Players:

Canine Stem Cell Therapy Market Segmentation:

The global market for Canine Stem Cell Therapy is set to find a segmentation in the report that would be based on type, and application. These segments have a better acceptance of various factors that can be taken into consideration to understand how the market can chart the future path.

Canine Stem Cell Therapy Market Breakdown by type

Canine Stem Cell Therapy Market Breakdown by Application

Any query or need customization? Ask here @ https://www.alltheresearch.com/customization/206

Regional Analysis Covered in Canine Stem Cell Therapy Report are:

Key Highlights of the Table of Contents:

Canine Stem Cell Therapy Market Study Coverage: It includes key market segments, key manufacturers covered, the scope of products offered in the years considered, global Canine Stem Cell Therapy Market and study objectives. Additionally, it touches on the segmentation study provided in the report on the basis of the type of product and applications.

Canine Stem Cell Therapy Market Executive summary: This section emphasizes the key studies, market growth rate, competitive landscape, market drivers, trends, and issues in addition to the macroscopic indicators.

Canine Stem Cell Therapy Market Production by Region: The report delivers data related to import and export, revenue, production, and key players of all regional markets studied are covered in this section.

Canine Stem Cell Therapy Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This segment also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Enquire More About Canine Stem Cell Therapy Market Research athttps://www.alltheresearch.com/speak-to-analyst/206

In this study, the years considered to estimate the market size of Canine Stem Cell Therapy Market:

History Year: 2015 2020

Base Year: 2020

Estimated Year: 2021

Forecast Year: 2021 2026

Reasons you should buy this report:

To Buy Full Report, Connect with us at:https://www.alltheresearch.com/buy-now/206

About Us

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

For All Your Research Needs, Reach Out to Us:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

https://farmingsector.co.uk/

Go here to see the original:
Canine Stem Cell Therapy Market Report 2026 Focuses on Top Companies, Research Methodology, Drivers and Opportunities - Farming Sector

A recent market study published by Reports Monitor consists of a detailed evaluation of the key market dynamics. The report provides past as well as present growth parameters of the global Canine Stem Cell Therapy Market. The report features important and unique factors, which are expected to significantly impact the growth of the global Canine Stem Cell Therapy Market throughout the forecast period 2021-2027.

It sheds light on the trends, restraints, and drivers to understand the growth chance followed by the key players in the global Canine Stem Cell Therapy Market.

Get a Sample PDF Report:https://www.reportsmonitor.com/request_sample/1192862

The Top Leading players operating in the market to Covered in this Report:VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet & More.

The report begin with a scope of the global Canine Stem Cell Therapy Market that includes the key findings and essential statistics of the market. This market research report also consists of the market value of the major segments of the global Canine Stem Cell Therapy Market. Reports Monitor has found a detailed classification and the definition of the global market that helps the readers to better understand the basic information of the Canine Stem Cell Therapy Market. It also highlights the exclusions and inclusions that help the client to understand the scope of the Canine Stem Cell Therapy Market.

Segment by Type, the product can be split intoAllogeneic Stem CellsAutologous Stem cellsMarket segment by Application, split intoVeterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

The report consists of key market trends, which are possible to impact the growth of the market over the forecast period 2021- 2027. Evaluation of in-depth industry trends is included in the report, along with their product innovations and key market growth.

Competitive Landscape:The report provides a list of all the key players in the Canine Stem Cell Therapy Market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product development, research, and development, and also provides revenue shares, company overview, and recent company developments to remain competitive in the market.

Regional Analysis For Canine Stem Cell Therapy Market:

North America(United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount! Please click [emailprotected]https://www.reportsmonitor.com/check_discount/1192862

In this study, the years considered to estimate the market size of the Canine Stem Cell Therapy are as follows:

What our report offers:

For More Details On this Report:https://www.reportsmonitor.com/report/1192862/Canine-Stem-Cell-Therapy-Market

Contact UsJay MatthewsDirect: +1 513 549-591481 (U.S.)+44 203 318 2846 (U.K.)Email:[emailprotected]

https://mmcthemonitor.com/

Originally posted here:
Canine Stem Cell Therapy Market with Competitive Analysis, New Business Developments and Top Companies: VETSTEM BIOPHARMA, Cell Therapy Sciences,...

In the United States, the most common of the aggressive non-Hodgkin lymphomas (NHLs) is diffuse large B-cell lymphoma (DLBCL), which accounts for between 22% and 24% of newly diagnosed B-cell NHL cases.1 Although DLBCL can affect children and young adults, it is most commonly diagnosed in individuals between the ages of 65 and 74 years, with a median age at diagnosis of 66 years.2,3 Given the aggressive nature of DLBCL, patients often present with lymphadenopathy, extranodal involvement, and other constitutional symptoms thatrequire immediate treatment.1

The treatment spectrum for DLBCL has expanded significantly in recent years, particularly for patients with relapsed or refractory (R/R) disease. Mechanisms of action differ greatly among agents, reflecting the complex pathophysiology and genetic variations of the disease. This article reviews the advances in DLBCL understanding that have led to the approval of new agents andsubsequent utilization of new mechanisms.

The current standards of care for first-line DLBCL treatment include the combination chemoimmunotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP). The varying numbers of cycles and use in combination with or without radiotherapy (RT) depends upon the stage of disease at presentation.1 The addition of rituximab to CHOP was associated with a 2-year event-free survival of 57% in elderly patients in a 2002 randomized trial (LNH-98.5), which, along with results of other trials, led to the FDA approval of this combination therapy.4,5 Although durable remission can be achieved with R-CHOP in about 60% of patients, its use has resulted in poorer long-term outcomes for patients with double-hit andtriple-hit lymphomas (DHL and THL).1

In 2007, the International Harmonization Project issued guidelines on malignant lymphoma response criteria, defining relapsed disease as consisting of new lesions greater than 1.5 cm in any axis during or after the completion of therapy or a 50% or greater increase in the sum of the product of diameters of a previously involved node(s) or other lesion(s).6 The authors also defined refractory, or progressive, disease as entailing a 50% or greater increase in the size of a lymph node with a prior short-axis diameter of less than 1.0 cm to a size of 1.5 cm 1.5 cm (or a long-axis size of > 1.5 cm).6

For patients with R/R disease, high-dose chemotherapy and autologous stem cell transplant (ASCT) may offer the chance for cure, but several factors may limit the utility of this approach. For example, in the treatment of patients with MYC-positive R/R DLBCL, ASCT is considered controversial because it has produced poorer outcomes in patients with DHL.1 Additionally, patients who are older or have comorbidities may be inappropriate candidates for this approach,7 and patients with disease that is unresponsive to second-line chemotherapy may have poorer prognoses (ie, poorer rates of long-term survival) and incur added toxicity from the chemotherapy.7 Even when including patients who undergo high-dose, salvage chemotherapy and subsequent ASCT, patients with R/R DLBCL have a 1-year survival rate of 28%.1 Hence, in a search for improved outcomes in the R/R setting, clinical studies have focused on DLBCL subtypes, especially in those ineligible for transplant or who have relapsed following transplant.1

Another option for patients in the relapsed setting is chimeric antigen receptor (CAR) T-cell therapy, which entails the genetic modification of autologous T cells via cloned DNA plasmids carrying a viral recombinant vector in addition to T-cell receptor-expressing genes. CAR T-cell therapy plays an important role in the R/R DLBCL setting, with reported 2-year remissions and a complete response (CR) rate in 40% of patients and 25% DHL/THL patients.1 Other therapeutic classes that have been explored for DLBCL include phosphoinositide 3-kinase (PI3K) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, and checkpoint inhibitors.1,8-10

Given reduced survival in patients who are unresponsive to subsequent lines of therapy and the toxicity involved, a great need exists for novel agents in the R/R DLBCL setting. Recent entrants to the R/R DLBCL treatment landscape include the antibody-drug conjugate (ADC) polatuzumab vedotin-piiq, the selective inhibitor of nuclear export, selinexor, and the monoclonal antibody tafasitamab-cxix (TABLE 111-20).

Polatuzumab vedotin-piiq was approved by the FDA in 2019 and is indicated in combination with bendamustine and rituximab in adults with RR DLBCL not otherwise specified, following at least 2 previous therapies.11 It is an ADC wherein the monoclonal antibody is linked to an antimitotic agent, monomethyl auristatin E (MMAE). The ADC targets the B-cell surface protein CD79B and, after binding to the surface protein, is internalized by the cell. Lysosomal enzymes then cleave the link between the antibody and MMAE, the latter of which binds microtubules, thereby inhibiting cell division and inducing apoptosis.11

A 2020 phase 1b/2 study (NCT02257567) randomized patients with R/R DLBCL who were ineligible for ASCT to receive polatuzumab vedotin-piiq with bendamustine and rituximab (pola-BR) or bendamustine and rituximab (BR) alone.12 The phase 2 primary end point was CR; secondary end points included overall response rate (ORR) at end of treatment, superior overall response, duration of response (DOR), and progression-free survival (PFS) assessed per independent review committee (IRC).12 With a median follow-up of 22.3 months, the CR was significantly higher in the pola-BR group (40% vs 17.5% in the BR group; P = .026).12 Overall survival rate was also significantly higher in the pola-BR group (12.4 vs 4.7 months in the BR group; HR, 0.42; 95% CI, 0.24-0.75; P = .002).12 Similarly, median PFS was significantly longer at 9.5 months in the pola-BR group compared with 3.7 months in the BR group (HR, 0.36; 95% CI, 0.21-0.63; P < .001).12 Also, DOR was longer at 12.6 months in the pola-BR group vs 7.7 months in the BR group (HR, 0.47; 95% CI, 0.19-1.14).12 Finally, the pola-BR group had a 58% reduction in risk of death compared with the BR group (HR, 0.42; 95% CI, 0.24-0.75; P = .002).12 In terms of safety, grade 3/4 anemia, neutropenia, thrombocytopenia, and peripheral neuropathy occurred more frequently in the pola-BR group than in the BR group.12 Polatuzumab vedotin-piiq was deemed an effective agent that might provide a therapeutic option for patients with R/R DLBCL who were not ideal candidates for CAR T-cell therapy.12

In 2020, selinexor was approved by the FDA for use in adult patients with R/R DLBCL (including follicular lymphoma-derived DLBCL) after at least 2 lines of systemic treatment.13 Selinexor inhibits nuclear export of tumor suppressor proteins by blocking exportin 1.13

The FDA approval was based on results of the open-label single-arm phase 2 SADAL trial (NCT02227251), which included patients 18 years or older with DLBCL (based on pathologic confirmation) with an Eastern Cooperative Oncology Group (ECOG) score of 2 or less, who had 2 to 5 lines of prior therapy, and who had progressed following or were ineligible for ASCT.14 The primary end point of the SADAL trial was ORR (comprising patients with CR or PR per 2014 Lugano criteria), with secondary end points consisting of DOR and disease control rate.14 Patients received the 60-mg oral selinexor on the first and third day of each week until disease progression or unacceptable toxicity occurred.14

The updated phase 2b ORR was 28.3% with a disease control rate of 37% (95% CI, 28.6-46.0). Of 36 responders, CRs were reported in 13 evaluable patients and PRs were reported in 23 patients. At a median follow-up of 11.1 months, the median DOR was 9.3 months (95% CI, 4.8-23.0). For those with a CR, median DOR was 23.0 months (95% CI, 10.4-23.0); median DOR was 4.4 months for those with a PR (95% CI, 2.0not evaluable).14,15 To address potential differences by subtype, the SADAL trial also included a subgroup analysis of patients with the germinal center B-cell (GCB)like subtype (n = 59), which demonstrated an ORR of 33.9%, a 14% CR rate, and a 20% PR rate, whereas the patients with a non-GCB subtype (n = 63) had an ORR of 20.6%. At the time of data cutoff, 7%(n = 9) of patients showed continuing response.14,15 The SADAL trial also included 5 patients with the unclassified subtype, in 1 of whom a CR was achieved and in 2 of whom a PR was achieved.15With respect to safety, 98% of patients in the SADAL trial had at least 1 treatment-emergent adverse event (TEAE). The most frequent grade 3/4 events were thrombocytopenia, neutropenia, anemia, fatigue, hyponatremia, and nausea.14 Among serious AEs affecting 48% of patients, the most common were pyrexia, pneumonia, and sepsis.14 Gastrointestinal AEs werereported in 80% of patients, hyponatremia in 61%, and central neurologic events (which included dizziness and altered mental status) in 25%.16 Trial investigators concluded that selinexor improved survival considerably and that it presented a nonchemotherapy oral option for patients with R/R DLBCL.14

Tafasitamab-cxix is a CD19-targeting monoclonal antibody that gained FDA approval in 2020 for use with lenalidomide in adults with R/R DLBCL who are ineligible for ASCT, including patients with low-grade lymphoma derived DLBCL.17 Tafasitamab-cxix binds to the pre-B and mature B-lymphocyte surface antigen CD19, which is expressed in DLBCL and other B-cell malignancies.17 Tafasitamab-cxix, once bound to CD19, facilitates B-lymphocyte lysis via apoptosis and immune effector mechanisms that encompass antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.17

The FDA approval of tafasitamab-cxix was based on data from the phase 2, single-arm, multicenter, open-label L-MIND trial (NCT02399085).17,18 The L-MIND trial included patients 18 years or older with R/R DLBCL who had received 1 to 3 previous therapies ( 1 of which incorporated a CD20-directed regimen), had an ECOG score of 0 to 2, and were ASCT ineligible.18 Patients were administered tafasitamab-cxix and lenalidomide in 28-day cycles and continued to receive tafasitamab-cxix every 2 weeks after cycle 12 until disease progression.18 Objective response rate (ie, PR and CR) was the primary end point per IRC, which implemented PET imaging; secondary end points included investigator-assessed objective response rate, DOR, OS, PFS, biomarker analyses, and safety.18 Eighty patients were included in the full analysis set (FAS), receiving tafasitamab-cxix plus lenalidomide.18 Of the FAS, the objective response rate was 60.0% (95% CI, 48.4%-70.8%) and the CR rate was 42.5% (34/80).18 The rate of patients achieving a 12-month DOR rate was comparable across subgroups, with 70.5% of patients who received 1 prior line of therapy achieving a 12-month DOR (95% CI, 47.2%-85.0%) and 72.7% of patients who had 2 or more prior lines of therapy achieving a 12-month DOR (95% CI, 46.3%-87.6%).18

Outcomes in patients with GCB DLBCL (n = 37) were promising, with an objective response rate of 48.6%, a 12-month DOR rate of 53.5%, and a 12-month OS rate of 65.4% (based upon the Hans algorithm). Outcomes in patients with non-GCB DLBCL (n = 21) were an improvement over those with the GCB subtype, with an objective response rate of 71.4%, a 12-month DOR rate of 83.1%, and a 12-month OS rate of 84.2%.18 IRC-evaluated data from a 2-year follow up of the L-MIND trial showed an objective response rate of 58.8% (47/80) and CR rate of 41.3% (33/80).19 The 2-year follow up data also showed a median DOR of 34.6 months, with a 31.6-month median OS and a 16.2-month median PFS.19

Safety data from the preliminary L-MIND trial results showed that the most frequent TEAEs (of any grade) were neutropenia (48%), thrombocytopenia (32%), anemia (31%), diarrhea (30%), pyrexia (22%), and asthenia (20%).20 A lenalidomide dose reduction was required in 42% of patients; 72% of patients could remain on daily lenalidomide at 20 mg or higher.20 Trial investigators concluded that the combination of tafasitamab-cxix and lenalidomide was well tolerated and did not lead to compounded AEs.20

The promising data from recent trialsparticularly from their DLBCL subtype based subgroupsunderscore the importance of understanding the unique prognoses and responses that these subtypes confer on patient outcomes. The establishment of DLBCL subtypes as prognostic and therapeutic response factors has fueled a search for more specific molecular targets in the disease process. In addition, the importance of subtype characterization is evidenced by ongoing diagnostic assay development (for use in conjunction with immunohistochemistry). As exemplified by the patient populations in these trials, new therapeutic options with distinct mechanisms of actions are needed for patients with R/R DLBCL who are ineligible for ASCT. Multiple studies of targeted agents in the R/R DLBCL setting are under way that include CAR T-cell, bispecific T-cell engager, programmed death receptor 1 (PD-1) inhibitor, and BCL2 inhibitor therapies.1 Continued development of clinically applicable diagnostics holds promise for improved prognostic capability and assessment of therapeutic response. With improved diagnostics, further elucidation of DLBCL-driver mutations can continue to provide additional DLBCL subtype-specific options and, hence, more treatments tailored to individual patients.

References1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-616. doi:10.1002/ajh.254602. Diffuse large B-cell lymphoma. Lymphoma Research Foundation. Accessed October 12, 2020. https://lymphoma.org/aboutlymphoma/nhl/dlbcl/3. Cancer stat facts: NHL diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. Accessed October 12, 2020. https://seer.cancer.gov/statfacts/html/dlbcl.html4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. doi:10.1056/NEJMoa0117955. Rituxan plus CHOP approved for diffuse large B-cell lymphoma. Cancer Network. February 28, 2006. Accessed November 6, 2020. https://www.cancernetwork.com/view/rituxan-plus-chop-approved-diffuse-large-b-cell-lymphoma6. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. doi:10.1200/JCO.2006.09.24037. Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192-196. doi:10.3816/CLML.2010.n.0308. Oki Y, Kelly KR, Flinn I, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017;102(11):1923-1930. doi:10.3324/haematol.2017.1728829. Ansell S, Gutierrez ME, Shipp MA, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood.2016; 128(22):183. doi:10.1182/blood.V128.22.183.18310. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698-2704. doi:10.1200/JCO.2015.65.978911. POLIVY. Prescribing information. Genentech, Inc; 2020. Accessed October 22, 2020. https://www.gene.com/download/pdf/polivy_prescribing.pdf12. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. doi:10.1200/JCO.19.0017213. XPOVIO. Prescribing information. Karyopharm Therapeutics, Inc; 2020. Accessed October 22, 2020. https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf14. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522. doi:10.1016/S2352-3026(20)30120-415. Karyopharm reports updated data from the phase 2b SADAL study at the 2019 International Conference on Malignant Lymphoma. News release. Karyopharm. June 19, 2019.Accessed June 28, 2020. https://www.globenewswire.com/news-release/2019/ 06/19/1871363/0/en/Karyopharm-Reports-Updated-Data-from-the-Phase-2b-SADAL-Study-at-the-2019-International-Conference-on-Malignant-Lymphoma.html16. FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma. News release. FDA. June 22, 2020. Accessed June 28, 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma17. Monjuvi. Prescribing information. MorphoSys US Inc; 2020. Accessed October 22, 2020. https://www.monjuvi.com/pi/monjuvi-pi.pdf18. Duell J, Maddocks KJ, Gonzalez-Barca E, et al. Subgroup analyses from L-Mind, a phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2019;134(suppl 1):1582. doi:10.1182/blood-2019-12257319. MorphoSys and Incyte announce long-term follow-up results from L-MIND study of tafasitamab in patients with r/r DLBCL. News release. Morpho-Sys. May 14, 2020. Accessed June 26, 2020. https://www.morphosys.com/media-investors/media-center/morphosys-and-incyte-announce-long-term-follow-up-results-from-l-mind20. Salles GA, Duell J, Gonzlez-Barca E, et al. Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-Mind. Blood. 2018;132(suppl 1):227. doi:10.1182/blood-2018-99-113399

Original post:
New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Targeted Oncology

HomeIn the last in a series on milestone anniversaries in politics and cultural history, produced with Huddersfield University, we recall the controversy generated by the first genetically modified food in Britain.

Saturday, 2nd January 2021, 6:00 am

It was only a tin of tomato puree, but it created a stink that lingered for years.

The 25th anniversary of the first genetically modified food to go on sale in a British supermarket merits scarcely a footnote in retailing history, yet it heralded a new scientific era. That same year, Dolly the sheep, the first mammal to have been successfully cloned from an adult cell, made her debut at Edinburgh University.

The cans of concentrated California puree that went on sale at Sainsburys and Safeway in February 1996 had been produced from the flavr savr tomato , a strain from which the rotting gene, not to mention most of the vowels, had been removed. The bioscience company Zeneca had spent 10 years perfecting the process, and said the result was a stronger tasting sauce that stuck better to pasta.

Critics, however, called it Frankenstein food and some threatened a boycott. The Prince of Wales said the implications of genetically modified cops were enough to send a cold chill down the spine.

The tins stayed on the shelves for three years before demand subsided and the range was withdrawn. Today, Britain remains one of the few developed nations where such crops are not grown commercially, although modified oilseed rape, soybean, cotton-seed oil, maize and sugar beet are allowed to be imported.

But it is politics, not science that is holding back the tide, according to one Yorkshire expert.

As a scientist, and taking into account the laws and safety procedures that are in place, I dont see a problem, said Dr Dougie Clarke of Huddersfield Universitys School of Applied Sciences.

They create higher yields, there is less food waste and in third world countries where growing food in arid conditions is a problem, they now have drought-resistant crops that they can grow and sustain.

The issue, he said, was that while politicians were content to be led by science in their response to illness and disease, they were less willing to listen to the arguments for genetic modification.

The British government is more worried about the publics opinion than they really should be, he said. I understand that people are concerned that these modified crops might begin to wipe out the natural variety, but there are very good control measures in place to prevent that happening.

The campaign group Genewatch UK takes the opposite view, calling for protection for plants and animals from contamination by genetically modified organisms, and a ban on activities that would compromise human rights and food security.

The argument goes far beyond crops, and as Dr Clarke pointed out, the work carried out in Edinburgh 25 years ago had been the catalyst for many important medical developments.

In 1996 we were leading the world with Dolly the sheep, and the one good thing that the British government allowed was research in stem cells, which can replace damaged tissues, whereas America banned it at one stage.

Dollys arrival on July 5 1996 was for a while one of the worlds best kept secrets. It was not until the following February that news of her birth was made known.

Scientists produced her by inserting DNA from a single sheep cell into an egg and implanting it in a surrogate mother.

In America, President Bill Clinton set up a task force to examine the legal and ethical implications of cloning, but 25 years later the process has manifested itself in unexpected ways.

Quite apart from the medical research it engendered into Parkinsons Disease and other conditions, it spawned an industry in pet cloning for the benefit of people who cannot bear to say goodbye to a loved animal.

Many people will pay to get a copy of their pet. Companies in America and South Korea have been specialising in this since 2001, said Dr Clarke. The first dog to be cloned was an Afghan hound.

But the same technology is also being used for something of real use, in the cloning of sniffer dogs that are used to search out explosives or drugs. Only a very small number usually make the grade, but Korean scientists managed to clone a golden Labrador retriever that was renowned for its sniffing abilities, and made several clones of it.

Not everyone likes the idea of that, but its clear that good can come from cloning.

Human closing, however, would likely remain beyond the pale, he said. In theory its completely possible, but no-one has done it and most people would consider it totally unethical.

Opinion was divided when Dolly the cloned sheep apparently named after the singer Dolly Parton was revealed to the world. Critics feared that the technique could be used to artificially produce humans, a prospect described by Dr Ian Wilmut, who led the team of scientists behind the project, as repugnant as well as illegal.

But he said the work would enable us to study genetic diseases for which there is presently no cure.

Many animal rights activists were horrified at the development, and the Church of Scotland said that while the work was fascinating, it had reservations about the implications.

Support The Yorkshire Post and become a subscriber today. Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, youll see fewer ads on site, get free access to our app and receive exclusive members-only offers. Click here to subscribe.

Read more:
25 years on, what is the legacy of Dolly the Sheep, and what future for GM food? - Yorkshire Post

The size of the global Canine Stem Cell Therapy market is expected to grow in the forecast period from 2020 to 2027, with a CAGR of XX. x% over the forecast period from 2020 to 2027 and is expected to reach XXX. X million by 2027, starting at XXX. X million in 2019.

A new informative report on the global Canine Stem Cell Therapy market titled as, Canine Stem Cell Therapy has recently published by Global Market Vision to its humongous database which helps to shape the future of the businesses by making well-informed business decisions. It offers a comprehensive analysis of various business aspects such as global market trends, recent technological advancements, market shares, size, and new innovations. Furthermore, this analytical data has been compiled through data exploratory techniques such as primary and secondary research. Moreover, an expert team of researchers throws light on various static as well as dynamic aspects of the global Canine Stem Cell Therapy market.

For Sample Copy of this Reports: https://www.globalmarketvision.com/sample_request/23873

The report presents a thorough overview of the competitive landscape of the global Canine Stem Cell Therapy Market and the detailed business profiles of the markets notable players. Threats and weaknesses of leading companies are measured by the analysts in the report by using industry-standard tools such as Porters five force analysis and SWOT analysis. The Canine Stem Cell Therapy Market report covers all key parameters such as product innovation, market strategy for leading companies, Canine Stem Cell Therapy market share, revenue generation, the latest research and development and market expert perspectives.

Some of the key players profiled in the Canine Stem Cell Therapy market include: VETSTEM BIOPHARMA

Cell Therapy Sciences

Regeneus

Aratana Therapeutics

Medivet Biologics

Okyanos

Vetbiologics

VetMatrix

Magellan Stem Cells

ANIMAL CELL THERAPIES

Stemcellvet

The main players in the Canine Stem Cell Therapy market are studies, and their strategies are analyzed to arrive at competitive prospects, current growth strategies and potential for expansion. In addition, the competitive landscape is due to the presence of market suppliers, numerous sales channels and revenue options. Contributions from industry experts as well as market leaders are an important factor in this study. Parents market trends, micro and macroeconomic factors, government stipulations and consumer dynamics are also studied in the writing of this report.Global Canine Stem Cell Therapy Market Segmentation:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):Allogeneic Stem Cells

Autologous Stem cells

Application Coverage (Market Size & Forecast, Consumer Distribution):Veterinary Hospitals

Veterinary Clinics

Veterinary Research Institutes

Regions Covered in the Global Canine Stem Cell Therapy Market:

The Middle East and Africa

North America

South America

Europe

Asia-Pacific

Get Special Discount: https://www.globalmarketvision.com/check-discount/23873

Scope of the report: This report describes the global Canine Stem Cell Therapy market, in particular in North America, South America, Africa, Europe and Asia-Pacific, and the Middle East. This report segments the market based on producers, regions, type and use. In the next time, Canine Stem Cell Therapy will have good demand, although the value may fluctuate due to the rapid transformation in the availability of raw materials and other resources.

Regionally, this market has been inspected across various regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, and Europe on the basis of productivity and manufacturing base. Some significant key players have been profiled in this research report to get an overview and strategies carried out by them. Degree of competition has been given by analyzing the global Canine Stem Cell Therapy market at domestic as well as a global platform. This global Canine Stem Cell Therapy market has been examined through industry analysis techniques such as SWOT and Porters five techniques.

Table of Content

1 Overview of the Canine Stem Cell Therapy market

2 Market competition by manufacturers

3 Production capacity by region 3 Production capacity by region

4 World consumption of Canine Stem Cell Therapy by region

5 Production, Turnover, Price trend by Type

6 Global Canine Stem Cell Therapy Market Analysis by Application

7 Company Profiles and Key Figures in Canine Stem Cell Therapy Business

8 Canine Stem Cell Therapy Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Production and Supply Forecast

12 Consumption and demand forecasts

13 Forecast by type and by application (2021-2026)

14 Research and conclusion

15 Methodology and data source

Continuous

Place a Direct Order Of this Report: https://www.globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=23873

For Any special requirements about this report, please let us know and we can provide custom reports.

Note In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Excerpt from:
Canine Stem Cell Therapy Market to Eyewitness Massive Growth by 2027: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics -...

Dr. Sen-itiroh Hakomori couldnt leave his lab work alone. He would often log 13-hour days, seven days a week, and even spend some time at his job on Christmas morning, intensely focused on his glycosphingolipid medical and biochemical research.

I realized fairly recently that all of the cells are just like a pet. You have to check up on them and make sure that things are going well because theyre alive, said his daughter Naoko Vaughn. As children, we did not understand why he went to work every single day. I realized that he had to.

Vaughns father, who she said had a heart of gold and would help anybody, died of natural causes at the age of 91 on Nov. 10 at his home on Mercer Island.

Roger Laine, a colleague and friend who was the last professor to visit Hakomori, said that he was truly a pioneering scientist in glycobiology, a field in which he spent seven decades participating in groundbreaking studies.

He worked most of his career showing differences between cancer cells and normal cells that could be targeted for therapy. If you asked him what was his goal in life, he would answer, cure cancer, said Laine, a professor, scientist and researcher at Louisiana State University.

Hakomori is survived by his wife, Mitsuko (they were married for 74 years); Vaughn; sons, Yoichiro and Kenjiro; four grandchildren and two great-grandchildren; two brothers and a sister.

A native of Japan, professor Hakomori made crucial contributions to new cancer-cell studies at the Cancer Research Institute at Tohoku Pharmaceutical University, and continued his vast research in the field when the family immigrated to the United States to the Boston area.

The family moved from Boston to Bellevue in the late 1960s and set up their new home on Mercer Island 46 years ago. Hakomori relocated his family to the Pacific Northwest to become involved with the Fred Hutchinson Cancer Research Center, and served as University of Washington professor of pathobiology and professor of microbiology. He was named a UW professor emeritus of pathobiology and global health in 2006.

Hakomori retired at the age of 88, finishing his career working at the Pacific Northwest Cancer Center in Seattle. During a celebration in Japan three years ago, Hakomori who was a member of the prestigious National Academy of Sciences spoke to the attendees and noted, We are all globally connected with research and science.

His two sons reflected on their fathers vital contribution to their lives.

Dad was passionate about his work and a great mentor to many of his younger colleagues. He has inspired me to try to emulate that passion in the work I do as an architect and professor, said Yoichiro.

Added Kenjiro: Dad taught me by example to work hard on trying to find out and work on resolving research questions it is a lifelong passion.

Vaughn added that her father instilled a high-level work ethic in his children, telling them, Whatever you do, whatever you choose to do, whatever your passion is, you do it 120 percent.

Hakomori made a worldwide impact with his research and was nominated five times for the Nobel Prize in chemistry. He received numerous awards, including the Philip Levine Immunohematology Award, the Karl Meyer Award from the Society of Glycobiology and the Rosalind Kornfield Award for Lifetime Achievement in Glycobiology.

He published 585 articles in peer-reviewed journals, and a pair of his many major scientific achievements were methylation analysis of glycoconjugates with mass spectrometry, and cell adhesion based on carbohydrate-carbohydrate interaction, particularly through GSL clusters at the embryonic stem cell surface.

He was very honored in his work, and he did not do it for money. He was very much just trying to help, which is rare these days, said Vaughn, adding that a host of his students and colleagues from around the world are assembling a memorial for her father to be published in a glycosphingolipid journal.

He was just a wonderful person. I think the most important thing is his colleagues really admired him. He made them successful in their lives, Vaughn added.

When Sarah Spiegel was a graduate student, she was drawn to Hakomoris papers and reviews on the role of glycoconjugates in cancer. Those documents sparked her imagination and inspired her to pursue a career in sphingolipids, she wrote on the Evergreen Washelli Funeral Home & Cemetery memorial page.

He was a champion of advancing careers of young female scientists and his generous spirit influenced my generation and generations to come, said Spiegel, Ph.D., professor and chair in the Department of Biochemistry and Molecular Biology at the Virginia Commonwealth University School of Medicine. His legacy will live on through the works of countless researchers who continue working in the field of sphingolipids and many colleagues throughout the world will miss him tremendously.

In consideration of how we voice our opinions in the modern world, weve closed comments on our websites. We value the opinions of our readers and we encourage you to keep the conversation going.

Please feel free to share your story tips by emailing editor@mi-reporter.com.

To share your opinion for publication, submit a letter through our website https://www.mi-reporter.com/submit-letter/. Include your name, address and daytime phone number. (Well only publish your name and hometown.) We reserve the right to edit letters, but if you keep yours to 300 words or less, we wont ask you to shorten it.

The rest is here:
'He was very honored in his work' - Mercer Island Reporter